公开(公告)号：ES2675858T3

公开(公告)日：2018-07-13

申请号：ES15721912

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K45/06 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K31/404 ,  A61K31/47 ,  C07D209/04 ,  C07D215/00

Abstract: Una composición farmacéutica que comprende: una primera dispersión secada por pulverización y una segunda dispersión secada por pulverización, en donde la primera dispersión secada por pulverización comprende del 70% en peso a aproximadamente el 90% en peso de una forma amorfa de (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6- fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1H-indol-5-il)ciclopropanocarboxamida (Compuesto 1) y de aproximadamente el 10% en peso a aproximadamente el 30% en peso de un polímero, en donde el polímero comprende hidroxipropilmetilcelulosa, y en donde la segunda dispersión secada por pulverización comprende una forma amorfa de N-[2,4-bis(1,1- dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida (Compuesto 2); en donde la composición farmacéutica es un comprimido que comprende de aproximadamente 25 mg a 125 mg de Compuesto 1 y de aproximadamente 100 mg a 200 mg de Compuesto 2.

公开(公告)号：NZ629199A

公开(公告)日：2017-01-27

申请号：NZ62919913

申请日：2013-02-27

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  JAMZAD SHAHLA ,  CAESAR JOHN P JR ,  FAWAZ MAJED ,  DAS LAURA ,  GU CHONG-HUI ,  HURTER PATRICIA NELL ,  ISRANI MEGHNA JAI ,  JOHNSTON MEGHAN M ,  KNEZIC DRAGUTIN ,  KUZMISSION ANDREW G ,  WANG HONGREN

IPC: A61K31/47 ,  A61K9/16 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: The disclosure relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating CFTR mediated disease in a pediatric patient employing the pharmaceutical composition, wherein the CFTR mediated disease is cystic fibrosis, COPD, emphysema, dry-eye disease or osteoporosis. Particularly disclosed is a pharmaceutical composition comprising: about 35 wt% of a solid dispersion by weight of the composition, wherein the dispersion comprises about 80 wt% by weight of the dispersion of substantially amorphous or amorphous Compound 1, wherein less than about 15% of Compound 1 is in crystalline form, about 19.5 wt% of hydroxylpropylmethylcellulose acetate succinate (HPMCAS) by weight of the dispersion, and about 0.5 wt% sodium lauryl sulfate (SLS) by weight of the dispersion; about 13.5 wt% of mannitol by weight of the composition; about 41 wt% of lactose by weight of the composition; about 2 wt% of sucralose by weight of the composition; about 6 wt% of croscarmellose sodium by weight of the composition; about 1 wt% of colloidal silicon dioxide by weight of the composition; and about 1.5 wt% of magnesium stearate by weight of the composition.

公开(公告)号：CA2944140A1

公开(公告)日：2015-10-22

申请号：CA2944140

申请日：2015-04-14

Applicant: VERTEX PHARMA

Inventor： PHENIX BRIAN DEAN ,  BAGNOL LAURENT JEAN-CLAUDE ,  BRODEUR GEOFFREY GLEN ,  CHANDRAN SACHIN ,  DOKOU ELENI ,  FERRIS LORI ANN ,  KNEZIC DRAGUTIN ,  MCCARTY KATIE LYNN ,  MEDEK ALES ,  WAGGENER SARA A

IPC: A61K9/14 ,  A61K31/404 ,  A61K31/47 ,  A61P43/00

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

公开(公告)号：MX2014010253A

公开(公告)日：2014-11-12

申请号：MX2014010253

申请日：2013-02-27

Applicant: VERTEX PHARMA

Inventor： JAMZAD SHAHLA ,  CAESAR JOHN P JR ,  FAWAZ MAJED ,  DAS LAURA ,  GU CHONG-HUI ,  HURTER PATRICIA NELL ,  JOHNSTON MEGHAN M ,  KUZMISSION ANDREW G ,  DOKOU ELENI ,  ISRANI MEGHNA JAI ,  KNEZIC DRAGUTIN ,  WANG HONGREN

IPC: A61K31/47 ,  A61K9/16 ,  A61K47/02 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: La presente invención se refiere a composiciones farmacéuticas que contienen una dispersión sólida de N-[2,4-Bis(1,1-dimetilletil )-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida incluyendo formulaciones de dispersiones sólidas en polvos, gránulos y minicomprimidos, métodos para fabricar y procesar los polvos, gránulos y minicomprimidos, y métodos para tratar fibrosis quística empleando la composición farmacéutica.

公开(公告)号：AU2009288200A1

公开(公告)日：2010-03-11

申请号：AU2009288200

申请日：2009-08-28

Applicant: VERTEX PHARMA

Inventor： DOKOU ELENI ,  GASPARAC REHELA ,  KNEZIC DRAGUTIN ,  KLINE BILLIE ,  JURKAUSKAS VALDAS

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48

Abstract: An immediate release formulation of an active ingredient.